CLINICAL SIGNIFICANCE OF COMBINING BCR-ABL1 TRANSCRIPT LEVELS AT 3 AND 6 MONTHS IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FRONTLINE SECOND-GENERATION TYROSINE KINASE INHIBITORS

被引：0
|
作者：
Lee, S. E. [1 ,2 ]
Choi, S. Y. [2 ]
Kim, S. H. [2 ]
Oh, Y. J. [2 ]
Chae, M. J. [2 ]
Song, H. Y. [2 ]
Yoo, H. L. [2 ]
Lee, M. Y. [2 ]
Jang, E. J. [2 ]
Jeong, K. H. [2 ]
Lee, J. S. [2 ]
Kim, D. W. [1 ,2 ]
机构：
[1] Catholic Univ Korea, Seoul St Marys Hosp, Dept Hematol, Seoul, South Korea
[2] Catholic Univ Korea, Canc Res Inst, Seoul, South Korea
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1546
引用
收藏
页码：599 / 599
页数：1
相关论文
共 50 条
  • [1] Assessment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
    Katalinic, D.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S100 - S100
  • [2] Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
    Marin, David
    Ibrahim, Amr R.
    Lucas, Claire
    Gerrard, Gareth
    Wang, Lihui
    Szydlo, Richard M.
    Clark, Richard E.
    Apperley, Jane F.
    Milojkovic, Dragana
    Bua, Marco
    Pavlu, Jiri
    Paliompeis, Christos
    Reid, Alistair
    Rezvani, Katayoun
    Goldman, John M.
    Foroni, Letizia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 232 - 238
  • [3] Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
    Rosti, Gianantonio
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Palandri, Francesca
    Baccarani, Michele
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 (02) : 159 - 170
  • [4] Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
    Neelakantan, Pratap
    Gerrard, Gareth
    Lucas, Claire
    Milojkovic, Dragana
    May, Philippa
    Wang, Lihui
    Paliompeis, Christos
    Bua, Marco
    Reid, Alistair
    Rezvani, Katayoun
    O'Brien, Stephen
    Clark, Richard
    Goldman, John
    Marin, David
    BLOOD, 2013, 121 (14) : 2739 - 2742
  • [5] BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
    Cuellar, Sandra
    Vozniak, Michael
    Rhodes, Jill
    Forcello, Nicholas
    Olszta, Daniel
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 433 - 452
  • [6] IMPACT OF BCR-ABL1 TRANSCRIPT TYPE IN CHRONIC MYELOID LEUKEMIA TREATED FRONTLINE WITH NILOTINIB
    Castagnetti, F.
    Gugliotta, G.
    Breccia, M.
    Stagno, F.
    D'Adda, M.
    Levato, L.
    Angelucci, E.
    Martino, B.
    Tiribelli, M.
    Fava, C.
    Binotto, G.
    Capodanno, I.
    Bocchia, M.
    Bergamaschi, M.
    Russo-Rossi, A.
    Cavazzini, F.
    Abruzzese, E.
    Soverini, S.
    Foa, R.
    Cavo, M.
    Martinelli, G.
    Saglio, G.
    Pane, F.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2017, 102 : 729 - 729
  • [7] Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Breccia, Massimo
    Stagno, Fabio
    D'Adda, Mariella
    Levato, Luciano
    Carella, Angelo Michele
    Martino, Bruno
    Tiribelli, Mario
    Fava, Carmen
    Binotto, Gianni
    Avanzini, Paolo
    Bocchia, Monica
    Bergamaschi, Micaela
    Rossi, Antonella Russo
    Cavazzini, Francesco
    Abruzzese, Elisabetta
    Soverini, Simona
    Alimena, Giuliana
    Cavo, Michele
    Martinelli, Giovanni
    Pane, Fabrizio
    Saglio, Giuseppe
    Baccarani, Michele
    Rosti, Gianantonio
    BLOOD, 2016, 128 (22)
  • [8] Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Malik, Sara
    Hassan, Shahzeb
    Eskazan, Ahmet Emre
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (11) : 975 - 978
  • [9] BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution
    Ribeiro, Beatriz Felicio
    Vergilio, Bruna Rocha
    Martins Miranda, Eliana Cristina
    Almeida, Maria Helena
    Delamain, Marcia Torresan
    da Silveira, Rosana Antunes
    de Souza, Carmino Antonio
    Albuquerque, Dulcineia Martins
    Dos Santos, Andrey
    Duarte, Vagner Oliveira
    Oliveira-Duarte, Gislaine Borba
    Lorand-Metze, Irene
    Barbosa Pagnano, Katia Borgia
    ACTA HAEMATOLOGICA, 2015, 134 (04) : 248 - 254
  • [10] Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
    Kim, Sung-Hyun
    Menon, Hari
    Jootar, Saengsuree
    Saikia, Tapan
    Kwak, Jae-Yong
    Sohn, Sang-Kyun
    Park, Joon Seong
    Jeong, Seong Hyun
    Kim, Hyeoung Joon
    Kim, Yeo-Kyeoung
    Oh, Suk Joong
    Kim, Hawk
    Zang, Dae Young
    Chung, Joo Seop
    Shin, Ho Jin
    Do, Young Rok
    Kim, Jeong-A
    Kim, Dae-Young
    Choi, Chul Won
    Park, Sahee
    Park, Hye Lin
    Lee, Gong Yeal
    Cho, Dae Jin
    Shin, Jae Soo
    Kim, Dong-Wook
    HAEMATOLOGICA, 2014, 99 (07) : 1191 - 1196
12345